skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Trametinib (Code C77908)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Trametinib

Definition: An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MEK MAPK/ERK kinase) with potential antineoplastic activity. Trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity threonine/tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.

Display Name: Trametinib

Label: Trametinib

NCI Thesaurus Code: C77908 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2697961  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
MEK Inhibitor GSK1120212

External Source Codes: 
CAS Registry Number 871700-17-3 (see NLM ChemIDplus info)
FDA UNII Code 33E86K87QN
PDQ Closed Trial Search ID 599034
PDQ Open Trial Search ID 599034 (check for NCI PDQ open clinical trial info)
UMLS CUI C2697961

Other Properties:
     Name Value (qualifiers indented underneath)
Accepted_Therapeutic_Use_For metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation; unresectable or metastatic melanoma with BRAF V600E or V600K mutations
Chemical_Formula C26H23FIN5O4
code C77908
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name MEK_Inhibitor_GSK1120212
Semantic_Type Organic Chemical
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom